Flu shots do work, but not the way most people expect. They won’t guarantee you never get the flu. What they reliably do is cut your chances of getting sick, and if you do catch the flu anyway, they make it significantly less likely to send you to the hospital or kill you. In the most recent full season (2023-2024), the vaccine reduced flu-related doctor visits by 33% to 67% depending on age, and reduced hospitalizations by 41% to 61%.
How Well the Vaccine Prevents Illness
Effectiveness varies by age group, and kids consistently get the biggest benefit. During the 2023-2024 season, children and teens aged 6 months to 17 years saw a 59% to 67% reduction in flu-related outpatient visits and a 52% to 61% reduction in hospitalizations. For adults 18 and older, the numbers were lower: a 33% to 49% reduction in outpatient visits and 41% to 44% against hospitalization.
Those numbers shift every year because the flu virus itself shifts. The vaccine is reformulated annually based on predictions about which strains will circulate. When those predictions line up well, effectiveness in some studies has reached around 29% in matched seasons versus essentially zero in mismatched ones. A decade-long analysis found that mismatched seasons, where the vaccine strains didn’t match what was actually circulating, were common enough to drag down the long-term averages significantly.
This is the core tension with flu vaccines. They’re built on an educated guess about a moving target. Some years the guess is excellent, other years it’s off. But even in mediocre years, the vaccine tends to offer partial cross-protection that softens the blow.
What Happens When Vaccinated People Still Get Sick
This is where the flu shot’s value becomes clearest. Even when vaccination doesn’t prevent infection entirely, it acts like a head start for your immune system. Your body has already seen something resembling the virus and can mount a faster, stronger response.
A meta-analysis of hospitalized flu patients found that vaccination was associated with a 26% reduction in ICU admissions and a 31% reduction in death. Among hospitalized older adults specifically, the protection was even more striking: vaccination was linked to a 64% reduction in the odds of dying in the hospital, after adjusting for age, sex, and other health conditions.
So the honest answer to “do flu shots work” depends on what you mean by “work.” If you mean a near-guarantee against catching the flu, no. If you mean a meaningful reduction in your chances of getting seriously ill or dying from it, the evidence is strong.
Why Kids Benefit More Than Adults
Children consistently show higher vaccine effectiveness than adults for a straightforward biological reason: their immune systems are encountering flu viruses with fewer years of accumulated exposure. Adults, particularly older adults, have immune systems shaped by decades of previous infections and vaccinations, which can sometimes interfere with the response to a new vaccine formulation. Children’s immune responses tend to be more robust and more closely matched to the vaccine’s intended effect.
For the youngest children (6 months to 4 years), vaccine effectiveness against hospitalization reached 56% during the 2022-2023 season. For school-age kids 5 to 17, it was around 46%. Both groups showed meaningful protection, but the youngest children, who are also at highest risk of severe complications, got the biggest benefit.
The Strain-Matching Problem
Every February, the World Health Organization and national agencies like the FDA select which virus strains should go into the next season’s vaccine. For the upcoming 2025-2026 U.S. season, the FDA has recommended a trivalent vaccine targeting two influenza A strains (H1N1 and H3N2) and one influenza B strain. These selections are based on global surveillance of which viruses are circulating and how they’re evolving.
The challenge is that flu viruses mutate constantly. A strain that’s dominant in February may have drifted by the time flu season peaks in December or January. When the match is good, vaccination provides solid protection. When it’s poor, the vaccine may offer little benefit against infection, though it can still reduce severity.
There’s also a manufacturing problem. Most flu vaccines are still grown in chicken eggs, and the virus can pick up mutations during that process that make the final vaccine slightly different from the original target. These “egg-adapted” changes are well documented. During the 2022-2023 season, all egg-based vaccine strains for H3N2 carried mutations in key areas of the virus’s surface protein. Cell-based and recombinant vaccines, which skip the egg-growing step, didn’t carry those mutations, making them a potentially better match to circulating viruses.
Stronger Options for Older Adults
Adults 65 and older face two challenges: they’re at highest risk for severe flu complications, and their immune systems respond less vigorously to standard vaccines. High-dose flu vaccines, which contain more of the active ingredient, were developed specifically for this group.
A large randomized trial found that the high-dose vaccine reduced hospitalizations for heart and lung diseases by about 6% and cardiovascular hospitalizations by about 7% compared to the standard-dose vaccine in adults 65 and older. Those margins sound small, but across millions of older adults, they translate to thousands of prevented hospitalizations each season. The benefit held regardless of whether participants had diabetes.
Protection Beyond the Flu Itself
One of the more surprising findings in recent years is that flu vaccination appears to protect against heart attacks and strokes. Influenza infection triggers intense inflammation throughout the body, which can destabilize plaques in blood vessels and cause clots. A large meta-analysis involving more than 9,000 patients found that flu vaccination was associated with a 26% lower risk of heart attacks and a 33% reduction in cardiovascular deaths.
This means the flu shot’s real-world value extends beyond just preventing a week of fever and misery. For people with existing heart disease or risk factors, it functions partly as cardiovascular protection.
Timing and Duration of Protection
After vaccination, your body needs about two weeks to build up protective antibodies. This is why public health agencies push for vaccination in September or October, well before flu activity typically peaks in December through February. If you wait until flu is already spreading widely in your community, you’re gambling on those two unprotected weeks.
Protection also fades over time. Antibody levels decline over the months following vaccination, which is why an annual shot is necessary. Getting vaccinated too early (say, July) could leave you with reduced protection by the tail end of flu season in March. The sweet spot for most people is September through October.
Why Population Coverage Matters
Flu vaccination doesn’t just protect the individual. When enough people in a community are vaccinated, the virus has fewer hosts to jump between, which slows transmission and indirectly protects people who can’t be vaccinated, like infants under 6 months. Modeling studies estimate that achieving herd immunity against seasonal flu requires roughly 30% to 40% vaccination coverage for a typical epidemic strain, though pandemic strains can require much higher rates.
U.S. public health targets call for 80% coverage in healthy individuals and 90% in high-risk groups. Current vaccination rates in both the U.S. and Europe fall short of what’s needed to establish true herd immunity, meaning the virus continues to circulate freely each season. Every additional person vaccinated chips away at that gap.